WaveMan
WaveMan · Company
PBM · Psyence Biomedical Ltd.
> Search tickers & screens ⌘K
LIVE
← All companies

PBM Psyence Biomedical (PBM) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001985062
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
8
13F, latest reported quarter

What the filings say about PBM

Activist stakes (13D), 180 days
1 filing
Largest: 30.1% of the class

Psyence Biomedical insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for PSYENCE BIOMEDICAL LTD. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
8 funds bought in last quarter
below 89% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.8% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 74% of Pharma & Biotech
The situation: each line is one rule over one dataset
Psyence Labs Ltd. disclosed a 5%+ stake (30.05%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PBM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns PBM: institutional holders (13F)

13F holdings, latest reported quarter
Parallel Advisors, LLC
178,750 sh
$575.4K
AdvisorShares Investments LLC
122,184 sh
$373.9K
MORGAN STANLEY
37,804 sh
$115.7K
JANE STREET GROUP, LLC
30,431 sh
$93.1K
XTX Topco Ltd
15,094 sh
$46.2K

Congress trades in PBM

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Psyence Labs Ltd.
Activist 13D · 2026-06-03
30.05%

PBM planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PBM mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Psychedelics ETF
$373.9K position · as of 2026-06-30
0.8%
Calamos Market Neutral Income Fund
$17.5K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 8 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PBM financials

Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-032024-032023-03
Net income$1.0M-$51.2M-$3.2M
SEC XBRL, fiscal years, as known on 2026-10-28

PBM Stock Sonar score 2/7 axes

Find similar shapesCompare
Institutional and government
11
Inputs
  • Funds adding, latest quarter8 · 11 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
74
Inputs
  • Short interest, % of float+1.8% · 74 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PBM filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 30.1% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies